Zika virus disease

Zika virus disease is a viral illness caused by Zika virus, described in the sources as a mosquito-borne flavivirus ^[1]. The virus was first isolated in 1947 in Uganda, and the same virus was also isolated from jungle-dwelling mosquitoes, indicating an ecological association with mosquito vectors ^[1]. Source-backed detail on classification beyond flavivirus identity, or on additional etiologic characteristics, is not yet available from the provided snippets ^[1][3].

The clinical spectrum is dominated by a high proportion of asymptomatic infection, with about 80% of infections reported as asymptomatic ^[1]. When illness occurs, it is described as mostly mild and may include fever, rash, arthralgia, and conjunctivitis ^[1]. The sources also document important fetal involvement, including a cluster of severe fetal malformations with microcephaly and ocular defects in northeast Brazil in 2015, with confirmed intrauterine infection ^[1]. Source-backed detail on course, duration, or other complications beyond these observations is not yet available ^[1][3].

Human infections were detected by serology and virus isolation in many areas of Africa and South Asia, and the disease was later recognized as an emerging infection with substantial cross-border spread ^[1][2]. The sources describe endemic circulation across tropical and subtropical regions of the world, with the highest reported risk of infection in Latin America and the Caribbean ^[3]. Although cases have declined globally since 2017, new outbreaks have still been reported, including in Asia in 2024 ^[3]. The literature also notes that fetal malformations were not recorded in Africa or Asia in the historical observations summarized by one source, while a major change in pathogenicity was observed after introduction to Brazil ^[1].

Transmission is described in the sources primarily as mosquito-borne, consistent with vector exposure ^[1]. Zika virus was isolated from jungle-dwelling mosquitoes, including Aedes (Stegomyia) africanus, supporting a mosquito vector ecology ^[1]. Source-backed detail on alternative routes of transmission, persistence, or specific exposure settings is not yet available in the provided material ^[1][3].

The supplied sources explicitly identify pregnant women as a group of particular concern because of the documented association with fetal malformations and because preventive interventions would be of special interest in this group ^[1][3]. Immunocompromised patients, including those living with HIV, are also mentioned as a group for whom prevention would be especially important ^[3]. Source-backed detail on additional high-risk groups is not yet available from the provided snippets ^[1][3].

The sources emphasize preventive rather than curative approaches, and note that no vaccine or treatment is available to date ^[3]. Multiple vaccines are in different clinical development stages, but phase 3 trials are awaiting the next epidemic ^[3]. The provided snippets also state that neutralizing monoclonal antibodies would be of interest, especially for pregnant women and immunocompromised patients, but source-backed detail on currently recommended public-health control measures is not otherwise specified ^[3].

In surveillance terms, Zika virus disease should be interpreted as an endemic but episodically outbreak-prone arboviral infection with major historic expansion across borders and recent localized resurgences ^[3][2]. Because about 80% of infections may be asymptomatic and illness is often mild, case detection may underestimate transmission intensity ^[1]. The sources also highlight significant cross-reactivity in diagnostics, particularly with dengue virus, so surveillance summaries should recognize that confirmatory specificity remains an important limitation ^[3].

1. 1 Slenczka W et al. Zika Virus Disease. Microbiol Spectr. 2016 Jun. PMID: 27337468. doi: 10.1128/microbiolspec.EI10-0019-2016. PubMed: https://pubmed.ncbi.nlm.nih.gov/27337468/
2. 2 Baker RE et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022 Apr. PMID: 34646006. doi: 10.1038/s41579-021-00639-z. PubMed: https://pubmed.ncbi.nlm.nih.gov/34646006/
3. 3 de Jong HK et al. Zika virus: an overview update. Curr Opin HIV AIDS. 2025 May 1. PMID: 40048580. doi: 10.1097/COH.0000000000000926. PubMed: https://pubmed.ncbi.nlm.nih.gov/40048580/
4. 4 Zika virus disease. International Journal of Community Medicine and Public Health. 2016. doi: 10.18203/2394-6040.ijcmph20161599. DOI: https://doi.org/10.18203/2394-6040.ijcmph20161599
5. 5 Zika Virus and Zika Virus Disease. Journal of Consumer Health on the Internet. 2017. doi: 10.1080/15398285.2017.1280340. DOI: https://doi.org/10.1080/15398285.2017.1280340
6. 6 Zika Virus Disease. Rising Contagious Diseases. 2024. doi: 10.1002/9781394188741.ch7. DOI: https://doi.org/10.1002/9781394188741.ch7

ICD-10

A92.5

ICD-11

1D47

Total cases

488K

Peak month

2016-03

Coverage

8 reporting countries · 2016-01-01 → 2026-06-20